Trials / Terminated
TerminatedNCT02475330
Dietary Flaxseed in NSCLC
Phase II Trial of Flaxseed to Prevent Pneumonopathy After Chemoradiation for Lung Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This single arm Phase II trial will investigate the feasibility of dietary flaxseed (FS) supplementation in subjects receiving definitive chemoradiotherapy for non-small cell lung cancer (NSCLC). Subjects will ingest FS for a period of approximately 8 to 9 weeks during the course of radiation treatment. Study participation and surveillance will last approximately 6 months. Subject specimen collection will include: blood, urine, and buccal swabs at 5 time points.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Flaxseed | Whole grain flaxseed diet consisting of 40g flaxseed ingested per day |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2018-08-01
- Completion
- 2018-08-01
- First posted
- 2015-06-18
- Last updated
- 2021-06-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02475330. Inclusion in this directory is not an endorsement.